Overview

Evaluate the Safety and Efficacy of Saroglitazar Mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL

Status:
Suspended
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety and efficacy of Saroglitazar Magnesium 1, 2, and 4 mg in patients with fasting triglyceride ≥500 mg/dL and ≤1500 mg/dL.
Phase:
Phase 2
Details
Lead Sponsor:
Zydus Discovery DMCC
Zydus Therapeutics Inc.